CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended		119 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
OPERATING EXPENSES
General and administrative	$ 222	$ 277	$ 674	$ 711	$ 33,329
Research and development	1,172	749	1,802	1,661	107,360
Purchased in-process research and development	0	0	0	0	34,311
Other	0	0	0	0	(375)
Total operating expenses	1,394	1,026	2,476	2,372	174,625
Interest and other income, net	(3)	3	(63)	(154)	(14,074)
Loss from continuing operations before taxes	1,391	1,029	2,413	2,218	160,551
Income tax benefit	0	(21)	0	(21)	(1,376)
Loss from continuing operations	1,391	1,008	2,413	2,197	159,175
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	0	0	(2,202)
NET LOSS	1,391	1,008	2,413	2,197	156,973
Less: Net Loss attributable to the noncontrolling interest	0	0	0	(193)	(667)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 1,391	$ 1,008	$ 2,413	$ 2,004	$ 156,306
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.03	$ 0.02	$ 0.06	$ 0.05
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,885